Fresenius Tempers Expectations For Adalimumab Biosimilar

 
• By Aidan Fry
  
Hand
Investors should not expect a major contribution to turnover this year from Fresenius Kabi's Idacio adalimumab biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products